Comparative Pharmacology
Head-to-head clinical analysis: BUPRENORPHINE HYDROCHLORIDE NALOXONE HYDROCHLORIDE versus NALOXEGOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPRENORPHINE HYDROCHLORIDE NALOXONE HYDROCHLORIDE versus NALOXEGOL.
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE vs NALOXEGOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial mu-opioid receptor agonist (buprenorphine) and mu-opioid receptor antagonist (naloxone). Buprenorphine has high affinity but low intrinsic activity at mu receptors, producing ceiling effects on respiratory depression and euphoria. Naloxone antagonizes opioid effects and is poorly absorbed sublingually, added to discourage parenteral abuse.
Naloxegol is a PEGylated derivative of naloxone, a mu-opioid receptor antagonist. As a peripherally acting mu-opioid receptor antagonist (PAMORA), it binds to and inhibits mu-opioid receptors in the gastrointestinal tract, reducing opioid-induced constipation without crossing the blood-brain barrier to affect central analgesia.
Sublingual: 2/0.5 mg to 4/1 mg once daily initially; titrate up to 8/2 mg, 12/3 mg, or 16/4 mg once daily; maximum 24/6 mg once daily. Buccal: 2.1/0.3 mg once daily initially; titrate up to 4.2/0.7 mg, 8.4/1.4 mg, or 12.6/2.1 mg once daily; maximum 12.6/2.1 mg once daily.
25 mg orally once daily in the morning, with or without food; may increase to 50 mg once daily if tolerated and needed.
None Documented
None Documented
Clinical Note
moderateNaloxegol + Digoxin
"The serum concentration of Digoxin can be increased when it is combined with Naloxegol."
Clinical Note
moderateNaloxegol + Levofloxacin
"The serum concentration of Levofloxacin can be increased when it is combined with Naloxegol."
Clinical Note
moderateNaloxegol + Prednisone
"The serum concentration of Prednisone can be increased when it is combined with Naloxegol."
Clinical Note
moderateNaloxegol + Hydrocortisone
Buprenorphine: terminal half-life 24-60 hours (mean ~37 h) due to slow dissociation from opioid receptors; clinically relevant for once-daily or alternate-day dosing. Naloxone: terminal half-life 1-2 hours; rapid elimination limits oral systemic availability.
Terminal elimination half-life is approximately 11-13 hours in patients with normal renal function; may be prolonged in severe renal impairment.
Buprenorphine: primarily fecal (69-70%) via biliary excretion; renal (10-30%) as unchanged drug and metabolites. Naloxone: extensively metabolized in liver, primarily conjugated; renal excretion of metabolites (70%), minimal unchanged (<1%).
Primarily fecal (approximately 66%) and renal (approximately 33%) as unchanged drug; <1% as metabolites.
Category A/B
Category C
Opioid Antagonist
Opioid Antagonist
"The serum concentration of Hydrocortisone can be increased when it is combined with Naloxegol."